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Background: Laminin-α2-deficient congenital muscular dystrophy (MDC1A) is a severe muscle-wasting disease for
which no curative treatment is available. Antagonists of the angiotensin II receptor type 1 (AT1), including the
anti-hypertensive drug losartan, have been shown to block also the profibrotic action of transforming growth factor
(TGF)-β and thereby ameliorate disease progression in mouse models of Marfan syndrome. Because fibrosis and
failure of muscle regeneration are the main reasons for the severe disease course of MDC1A, we tested whether
L-158809, an analog derivative of losartan, could ameliorate the dystrophy in dyW/dyW mice, the best-characterized
model of MDC1A.
Methods: L-158809 was given in food to dyW/dyW mice at the age of 3 weeks, and the mice were analyzed at the
age of 6 to 7 weeks. We examined the effect of L-158809 on muscle histology and on muscle regeneration after
injury as well as the locomotor activity and muscle strength of the mice.
Results: We found that TGF-β signaling in the muscles of the dyW/dyW mice was strongly increased, and that
L-158809 treatment suppressed this signaling. Consequently, L-158809 reduced fibrosis and inflammation in skeletal
muscle of dyW/dyW mice, and largely restored muscle regeneration after toxin-induced injury. Mice showed
improvement in their locomotor activity and grip strength, and their body weight was significantly increased.
Conclusion: These data provide evidence that AT1 antagonists ameliorate several hallmarks of MDC1A in dyW/dyW
mice, the best-characterized mouse model for this disease. Because AT1 antagonists are well tolerated in humans
and widely used in clinical practice, these results suggest that losartan may offer a potential future treatment of
patients with MDC1A.
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Losartan (CozaarW; Merck Sharpe & Dohme, White-
house Station, NJ, USA), is widely used in clinics to treat
hypertension, cardiomyopathy and chronic renal disease.
It is very well tolerated by all age groups. Losartan is a
potent inhibitor of angiotensin II receptor type 1 (AT1)
and thus lowers the blood pressure by directly causing
vasodilation, and by reducing secretion of vasopressin
and aldosterone. Activation of AT1 by angiotensin II
results in the production of thrombospondin (TSP)-1,* Correspondence: markus-a.ruegg@unibas.ch
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reproduction in any medium, provided the orwhich has been shown to be a key regulator of TGF-β
activation [1,2]. Therefore, AT1 inhibition and subse-
quent reduction of TSP-1 production has been shown to
block TGF-β activation [1].
TGF-β is a cytokine whose activity is known to inhibit
myoblast differentiation, promote fibrosis [3], and impair
regeneration capacity in muscle [4]. TGF-β signals via
phosphorylation of Smad2/Smad3, which then form a
complex with Smad4 that translocates into the nucleus,
where it modulates transcription [5]. TGF-β also acti-
vates the mitogen-activated protein kinases (MAPKs),
including extracellular signal-regulated kinase (ERK)1/2,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proteins or transcription factors [6,7]. Raised TGF-β
levels and activity were shown to contribute strongly to
the phenotype of several diseases [8-10]. For example,
Marfan syndrome (MFS), which is caused by mutations
in the gene encoding fibrillin-1 [11], is characterized by
increased fibrosis and impaired muscle regeneration [1].
Beside structural functions, fibrillin-1 negatively regu-
lates TGF-β signaling [9,10]. Consequently, mutations in
fibrillin-1 lead to increased TGF-β levels in muscles of
patients with MFS and in mouse models of MFS
(Fbn1C1039G/+) [1,12]. In addition, increased TGF-β
levels were found in muscles of Duchenne muscular dys-
trophy patients and mdx mice [8,10], and in old mice
suffering from sarcopenia [13]. Importantly, when
Fbn1C1039G/+ and mdx mice were treated with losar-
tan, AT1-mediated TGF-β signaling was inhibited,
decreased fibrosis, normalized muscle architecture, and
improved muscle function and regeneration [1,14,15]. In
mice with sarcopenia, losartan improved muscle remod-
eling after injury, and protected muscle from disuse-
induced atrophy [13].
Laminin-α2-deficient congenital muscular dystrophy
(MDC1A) is a severe muscle-wasting disease that leads
to death in early childhood [16]. MDC1A is caused by
mutations in the gene encoding the laminin-α2 chain,
which is needed to form the heterotrimeric laminin-211,
the main laminin isoform in the basement membranes
of muscle and peripheral nerve [17]. In MDC1A, ab-
sence of laminin-211 disrupts the linkage of the base-
ment membrane to the underlying cell layer, and
interrupts intracellular signaling. Consequently, muscle
fibers degenerate upon contraction as a result of the
poor mechanical stability, fail to regenerate properly
[18,19], and often undergo apoptosis [18,20]. The mus-
cles of patients with MDC1A and of mouse models of
MDC1A are characterized by extensive fibrosis, marked
variation in muscle fiber size, and a greatly impaired
ability of muscle to regenerate [19-25].
Over the last 10 years, various studies have been car-
ried out on MDC1A mouse models to test potential
treatment options. To date, transgenic expression of
laminin-α1, a homolog of laminin-α2, in laminin-α2-de-
ficient dy3K/dy3K mice has shown the highest efficacy in
restoring muscle function [26,27]. Similarly, a very pro-
found restoration of muscle is achieved by transgenic ex-
pression of mini-agrin, a miniaturized form of the
basement membrane component agrin in dy3K/dy3K [21]
and dyW/dyW mice [19,25]. Interestingly, expression of
mini-agrin by systemic delivery of recombinant adeno-
associated virus (AAV) has also been shown to have a
strong ameliorating effect in dyW/dyW mice [28].
Although these genetic therapies are interesting, the
translation of such approaches into clinical practiceremains difficult. Hence, several pharmacological
approaches have been tested, which would eventually
allow clinical treatment options. These include inhibition
of apoptosis in dyW/dyW mice [29-32] and interference
with proteasomal and autophagy-mediated degradation
of proteins [33,34], Halofuginone, an analog of a plant
alkaloid that blocks TGF-β-mediated collagen synthesis,
was tested in dy2J/dy2J mice, which represent a much
milder form of MDC1A that is caused by the partial loss
of laminin-211 [35]. In these mice, halofuginone was
shown to inhibit Smad3 phosphorylation downstream of
TGF-β activation and to prevent progression of fibrosis,
resulting in an amelioration of the dystrophic phenotype
[36]. Likewise, in dy2J/dy2J mice, losartan was shown to
inhibit TGF-β signaling, improve grip strength, and re-
duce fibrosis [37]. Besides the mouse data, there is evi-
dence that TGF-β levels are increased in muscles of
patients with MDC1A [38].
Therefore, we aimed to test the effect of the AT1 in-
hibitor L-158809, a potent derivative of losartan, in the
severe dyW/dyW mouse model for MDC1A. We found
that AT1-mediated TGF-β signaling contributes to the
pathology in MDC1A, and that L-158809 treatment
reduces TGF-β levels. Fibrosis was reduced and several
histological hallmarks of disease were improved. Import-
antly, L-158809 supported successful regeneration in
dyW/dyW muscles, and improved body weight, grip
strength, and locomotor activity. Taking into consider-
ation the fact that losartan is already in clinical use and
is well tolerated in all age groups, this treatment could
proceed to clinical testing quickly and, might be a sup-




All procedures were approved by the veterinary commis-
sion of the Canton Basel-Stadt, and were performed in
accordance with the Swiss regulations for animal
experimentation.
Treatment of dyW/dyW mice with the angiotensin II type 1
receptor antagonist L-158809
DyW/dyW mice served as the mouse model for MDC1A,
and were genotyped as previously described [24]. Age-
matched wild-type (WT) mice served as the control
group. To ensure optimal access of dyW/dyW mice to
water and food, cages were supplied with long-necked
water bottles, and wet food was placed inside the cage.
Mice were treated with L-158809 (5,7-dimethyI-2-
ethyI-3-[[2'-(−1 H-tetrazol-5yI)[1,1]-bi-phenyl-4-yl]-me-
thyl]-3 H-imidazo[4,5-b]pyridine: generously provided
by Merck Sharp & Dohme Research Laboratories, West
Point, PA, USA). L-158809 is a potent orally bioavailable
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more potent, chemically modified derivative of losartan
(DuP-553; Merck) [39]. L-158809 was solubilized in 15%
NaHCO3, then 0.6 g/L of L-158809 and 4% sucrose was
added to the drinking water. This solution was given
as drinking water and was used for the preparation of
the wet food. L-158809 treatment started at the age
of 3 weeks and was continued until the animals were
killed by CO2 asphyxiation at the age of 6 or 7 weeks.
L-158809 treatment did not influence the body weight,
muscle function, or muscle architecture of WT mice
(data not shown).
Masson trichrome and immunostaining
The triceps brachii and diaphragm muscles were
immersed in 7% gum Tragacanth (Sigma-Aldrich, St.
Louis, MO, USA) and rapidly frozen in liquid nitrogen-
cooled isopentane at −150°C). Cross-sections, 12 μm in
thickness, were cut using a cryostat (Leica CM 1950;
Leica Biosystems, Nussloch, Germany) and collected on
slides (SuperFrostW Plus; Thermo Fisher Scientific Inc.,
Rockford, IL, US). Masson's trichrome staining [40] was
performed to visualize collagenous tissue, using a com-
mercial kit (HT-15; Trichrome Stain Kit; Sigma-Aldrich).
The antibodies used for stainings were purchased
from commercial sources as follows. Monoclonal rabbit
anti-mouse TGF-β (56E4, CST #3709), monoclonal
rabbit anti-human phospho-Smad2(Ser465/467)/Smad3
(Ser423/425) antibody (CST #9510) (both Cell Signaling
Technology, Beverly, MA, USA) polyclonal rabbit anti-
human TSP 1 (LS-C26356; Lifespan Biosciences, Inc.,
Seattle, WA, USA), polyclonal rabbit anti-human perios-
tin (RD181045050; BioVendor LLC, Candler, NC, USA),
monoclonal rat anti-mouse F4/80 (ab6640; Abcam,
Cambridge, MA, USA), monoclonal mouse anti-rat de-
velopmental myosin heavy chain (dMyHC) (NCL-
MHCd; Novocastra, Norwell, MA, USA), monoclonal
rat anti-mouse laminin-γ1 chain (MAB1914; Chemicon
(now EMD Millipore, Billerica, MA, USA)). Membrane-
bound and extracellular epitopes were visualized with
Alexa-488-conjugated wheatgerm agglutinin (WGA)
(Molecular Probes, Eugene, OR, USA). Depending on
the source of the primary antibody, the appropriate Cy3-
conjugated (Jackson ImmunoResearch Laboratories,
West Grove, PA, USA) or Alexa FluorW 488-conjugated
(Molecular Probes) secondary antibodies or tetramethyl
rhodamine isothiocyanate (TRITC)-labeled streptavidin
were used for visualization. DAPI (4',6'-diamidino-2-
phenylindole hydrochloride) was used to stain nuclei.
Pictures of stained cross-sections were taken using a
fluorescence microscope (DM5000B; Leica, Heerbrugg,
Switzerland), a digital camera (F-View), and analySISW
software (both Soft Imaging Systems Corp, Lakewood,
CO, USA).Histological quantifications
The triceps brachii and diaphragm muscles were chosen
for histological analysis to exclude muscles that are
affected by the secondary atrophic effect resulting from
hind-limb paralysis, which is caused by demyelination of
the peripheral nerve [41]. Mid-belly cross-sections were
analyzed. Nuclear accumulation of pSmad2/3 was counted
in four corresponding squares on cross-sections stained
with phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425)
and DAPI. Fibrosis was quantified by measuring the
collagenous area on entire cross-sections stained with
Masson trichrome, and was normalized to muscle area.
F4/80 staining allowed counting of macrophages in four
corresponding squares in the triceps and in the entire
cross-section of the diaphragm. The muscle fiber-size
distribution was quantified on entire WGA-stained cross-
sections using the minimum distance of parallel tangents
at opposing particle borders (minimal Feret’s diameter) as
described previously [42]. The variance coefficient of the
muscle fiber size was defined as follows: variance
coefficient = (standard deviation of the muscle fiber size
÷ mean muscle fiber size) × 1000. Normalization of the
number of fibers in each Feret class of 5 μm was based on
the total fiber number per muscle. Fibers with centrally
located nuclei (centrally nucleated fibers; CNF) were
counted in the entire WGA/DAPI-stained cross-sections.
Regenerating dMyHC-positive fibers were quantified on
entire dMyHC/laminin-γ1/DAPI-stained cross-sections.
Only dMyHC-positive fibers that appeared to be healthy
were included. Because the antibody used to detect
dMyHC was raised in mice, the mean number of
dMyHC-positive fibers represents the mean number of
dMyHC-positive fibers minus the mean number of fibers
that were stained with the secondary antibody alone (that
is, 2.8 muscle fibers/cross-section in dyW-L158 mice and
9 fibers/cross-section in dyW/dyW mice). In all histological
quantification experiments, at least four mice from each
group were analyzed.
Western blotting analysis
Triceps brachii and diaphragm muscles were homoge-
nized in radio-immunoprecipitation assay (RIPA) protein
extraction buffer (Abcam). A commercial kit (23227;
BCA Protein Assay Kit; Pierce Biotechnology Inc., Rock-
ford, IL, USA) was used to determine protein concentra-
tions. Equal amounts of protein (20 μg) were separated
in 8% (periostin; 75 to 90 kDa) or 20% (transforming
growth factor (TGF)-β; 12 kDa in reducing conditions)
SDS–PAGE and transferred to nitrocellulose membrane.
The membrane was incubated with antibodies to perios-
tin (RD181045050; BioVendor) or TGF-β (PAB11274;
Abnova Corp., Taipei, Taiwan). An antibody to β-actin
(#4970; Cell Signaling Technology) was used as loading
control. For detection, the appropriate horseradish
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noreactivity was visualized using the enhanced chemilu-
minescence detection method (32106; Pierce).
Quantitative real-time PCR
The total RNA of the triceps brachii and diaphragm
muscles was extracted (#Z3105; SV Total RNA Isolation
System; Promega, Corp., Madison, QI, USA). Samples
were calibrated to equal amounts for cDNA synthesis using
a commercial kit (#170–8891; iScript cDNA Synthesis Kit;
Bio-Rad Laboratories, Inc., Hercules, CA, USA). SYBR
Green (4367659; Power SYBR Green PCR Master Mix) was
used to perform quantitative PCR in a PCR system
(4376600; StepOnePlus™ Real-Time PCR System; both Ap-
plied Biosystems, Foster City, CA, USA) with the following
primers for TGF-β1 (sense: 50 GACTCTCCACCTGCAA
GACCAT 30 and anti-sense: 50 GGGACTGGCGAGCCT
TAGTT 30) and on β-actin (sense: 50 CAGCTTCTTTG
CAGCTCCTT 30 and anti-sense: 50 GCAGCGATATCGT
CATCCA 30) for normalization. The ΔΔCt method was
used to analyze changes in TGF-β1 mRNA expression rela-
tive to WT levels.
Hydroxyproline assay
Fibrosis in the triceps brachii muscles was measured by
assaying for the exclusive collagen-specific modified
amino acid hydroxyproline. Tendons were carefully
removed before muscles were speed-dried under vac-
uum and sent for amino acid analysis (Analytical
Research Services; Bern, Switzerland) as described pre-
viously [19]. There, muscles were hydrolyzed, then
evaporated to dryness, and resuspended in 0.1% tri-
fluoroacetic acid. Amino acids were determined by a
routine method [43] using high-performance liquid
chromatography (HPLC) to identify and quantify the
amino acid hydroxyproline. The relative hydroxyproline
amount was assessed with reference to the total amount
of amino acids.
Notexin-induced muscle damage
The tibialis anterior (TA) muscle of 5 week-old mice
was injured by injection of 15 μl notexin (50 μg/ml;
Sigma-Aldrich) as described previously [21]. Mice were
killed 5 days after injection, and muscles were isolated
and processed as described above.
Body weight, locomotion, and grip strength
Body weight was measured at the age of 7 weeks before
mice were sacrificed. Locomotive behavior was recorded
by placing the mice into a new cage and measuring
motor activity (walking, digging, stand-ups on hindlegs)
for 10 minutes [25]. Grip strength was evaluated by pla-
cing the animals onto a vertical grid, and measuring
the time until they fell down; the cut-off time was180 seconds. In all tests, at least 12 animals of each
genotype were analyzed, and values were normalized to
those obtained from WT animals.
Statistical analysis
To compare the different genotypes, P-values were
calculated using the one-way ANOVA test.
Results
Angiotensin II receptor type 1 (AT1) signaling and TGF-β
levels are increased in dyW/dyW mice
In the first set of experiments, we tested whether TGF-β
levels were increased in muscles of laminin-α2-deficient
dyW/dyW mice. We found that TGF-β (Figure 1, green
staining) was present in the perimysium and endomy-
sium of triceps muscle from dyW/dyW mice, but was ab-
sent in WT mice (Figure 1A). Accordingly, expression of
periostin and nuclear accumulation of phosphorylated
Smad2/3 complexes (pSmad2/3), both downstream med-
iators of TGF-β signaling, were seen in dyW/dyW but not
in WT triceps (Figure 1A). Western blotting analysis
confirmed the presence of TGF-β and periostin in dyW/
dyW muscles (Figure 1B, first panel).
To test whether L-158809 decreased TGF-β levels, we
treated dyW/dyW mice with L-158809 for 3 weeks. Stains
and immunoblots of triceps muscles from the treated
dyW/dyW mice (dyW-L158) showed a strong reduction in
TGF-β and periostin (right panels, Figure 1A and
Figure 1B). Correspondingly, nuclear accumulation of
pSmad2/3 complexes was 25 times higher in dyW/dyW
than in WT muscles, but was reduced to almost WT
levels after L-158809 treatment (Figure 1A, right panel;
Figure 1C). The suppression of TGF-β by L-158809 was
also seen for mRNA levels, which were less than 50% of
those in dyW/dyW mice (Figure 1D). Importantly, TSP-1,
which is increased by AT1 signaling [44], and has been
shown to mediate activation of TGF-β in cardiac muscle
and kidney [45], was present in the extracellular matrix of
dyW/dyW mice, but was strongly reduced in L-158809-
treated dyW/dyW triceps and diaphragm muscle (Figure 1E).
These results indicate that AT1-mediated TGF-β signaling
is increased in MDC1A , and that L-158809 dampens this
pathway.
Angiotensin II type 1 receptor antagonism improves
fibrosis, inflammation, and overall histology
To test for a beneficial effect of L-158809, we treated
dyW/dyW mice starting at the age of 3 weeks and con-
tinuing until the age of 7 weeks. First, we analyzed
the potential of L-158809 to reduce fibrosis and inflam-
mation in triceps and diaphragm muscle of dyW/dyW
mice. Masson trichrome staining showed a more prom-
inent replacement of muscle tissue with non-muscle
cells in untreated dyW/dyW mice than in mice treated
Figure 1 L-158809 lowered angiotensin II receptor type 1 (AT1)
-mediated transforming growth factor (TGF)-β levels in the
muscles of dyW/dyW mice. (A) AT1-mediated TGF-β levels were
increased in muscles of dyW/dyW mice and decreased after L-158809
administration. Triceps cross-sections of dyW/dyW mice showed
expression of TGF-β (green) and periostin (green), and nuclear
accumulation of pSmad2/3 (green), which is a downstream target of
AT1. Oral L-158809 treatment of dyW/dyW mice (dyW-L158) reduced
expression of all three proteins. Nuclei were visualized with 4',6'-
diamidino-2-phenylindole hydrochloride (DAPI) (blue). (B) Western
blotting analysis of triceps muscles confirmed increased protein
expression levels of periostin (75 to 85 kDa) and TGF-β (12 kDa,
reduced) in dyW/dyW mice as well as the reduction after L-158809
treatment. β-actin was used as a loading control. (C) The number of
pSmad2/3-positive nuclei was more than 25-fold increased in cross-
sections of dyW/dyW muscle compared with wild-type (WT) muscles,
and was significantly reduced by L-158809 to levels 2-fold (triceps)
and 2.6-fold (diaphragm) those of WT mice, which was not
significant (n ≥ 4). (D) Quantitative real-time PCR showed an
increase of approximately 3.5-fold in TGF-β1 mRNA levels in both
dyW/dyW triceps and diaphragm muscles, which was reduced to
nearly WT levels by L-158809 (n ≥ 4). (E) Thrombospondin-1 (green)
was increased in both triceps and diaphragm muscles of dyW/dyW
mice, and was minimized by L-158809 administration. All values
represent the mean ± SEM. One-way ANOVA: **P ≤ 0.001;
* P ≤ 0.05; n.s. (non-significant) P > 0.05. Scale bar = 50 μm.
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collagen, suggests that the non-muscle cells found in un-
treated muscles represent mainly fibrotic tissue
(Figure 2A). The fibrotic area measured in cross-sections
of triceps and diaphragm muscle of dyW/dyW mice trea-
ted with L-158809 was less than 50% of that seen in un-
treated mice (Figure 2B). As an independent measure of
fibrosis, we also determined the hydroxyproline content
in triceps muscles. In agreement with the histological
measurements, L-158809 reduced the hydroxyproline
content in dyW/dyW muscles (Figure 2C). Because TGF-
β plays an important role in regulating skeletal-muscle
inflammation [38,46], we also assessed inflammation
using the F4/80 antibody that recognizes activated
macrophages (Figure 2D,E). Macrophages were mainly
located in areas where muscle fiber degeneration is tak-
ing place (Figure 2D). In untreated dyW/dyW muscles,
around 100 macrophages were found per mm2, whereas
L-158809 reduced this number by six times in triceps
and by three times in diaphragm muscle (Figure 2E).
These data provide evidence that L-158809 inhibits and
thus minimizes TGF-β-induced fibrosis and inflamma-
tion in muscles of dyW/dyW mice.
We next investigated whether the L-158809-mediated
reduction of fibrosis also ameliorated other histological
hallmarks of MDC1A. A prominent feature of laminin-
α2-deficient muscles is the loss of muscle fibers, which
is probably due to muscle degeneration and the difficulty
in muscle regeneration [18]. Indeed, the number of
muscle fibers in dyW/dyW mice was much lower than in
Figure 2 (See legend on next page.)
Meinen et al. Skeletal Muscle 2012, 2:18 Page 6 of 13
http://www.skeletalmusclejournal.com/content/2/1/18
(See figure on previous page.)
Figure 2 L-158809 reduces fibrosis and inflammation in the muscles of dyW/dyW mice. (A) Masson trichrome staining showed higher
collagen content (blue) in triceps and diaphragm muscles of dyW/dyW when compared with dyW-L158 mice. (B) Average amount of fibrotic area
relative to wild-type (WT) muscles. L-158809 treatment more than halved the fibrotic area in triceps and diaphragm muscles (n ≥ 4).
(C) Measurement of the amount of hydroxyproline as an indicator of fibrosis. L-158809 treatment of dyW/dyW mice reduced the hydroxyproline
amount in triceps muscle (n = 3). (D) F4/80 staining of macrophages in diaphragm muscles. (E) L-158809 treatment reduced the number of
macrophages in muscles of dyW/dyW mice (n ≥ 4). All values represent the mean ± SEM. One-way ANOVA: **P ≤ 0.001; * P ≤ 0.05; n.s.
(non-significant) P > 0.05. Scale bar = 50 μm.
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losing 46% and 40% of their fibers (Figure 3A). L-158809
decreased this fiber loss in triceps muscle, and increased
the fiber number to 68% of WT. In diaphragm,
L-158809 showed a similar trend, but this was not sig-
nificant (Figure 3A). Further, L-158809 did not affect
fiber size distribution in dyW/dyW triceps muscle
(Figure 3B). In diaphragm, where muscle fiber-size dis-
tribution was only slightly shifted to smaller diameters
in dyW/dyW mice, L-158809 shifted fiber-size distribu-
tion only slightly towards the values in WT (Figure 3C).
Accordingly, the minimal Feret’s variance coefficient [42]
was increased in dyW/dyW muscles but was not cor-
rected by L-158809 (Figure 3D). However, because of
the higher number of muscle fibers in L-158809-treated
dyW/dyW mice, the mean cross-section area of the
muscle was significantly increased (Figure 3E). Thus,
L-158809 partially prevents the loss of muscle fibers, but
does not significantly affect the diameter of dyW/dyW
muscle fibers.L-158809 strongly improves spontaneous and injury-
induced muscle regeneration
The muscles of dyW/dyW mice are strongly impaired in
muscle regeneration [18,19,21]. In addition, increased
TGF-β activity leads to failure of muscle regeneration
[1]. Therefore, L-158809 may improve regeneration of
dyW/dyW muscle. However, the number of centrally
nucleated fibers, which are indicative of ongoing degen-
eration/regeneration, were not significantly increased
after L-158809 administration (Figure 4A). By contrast,
staining of diaphragm muscle with the regeneration
marker dMyHC (Figure 4B, green) indicated that more
fibers regenerated after L-158809 treatment of dyW/dyW
mice. Muscle fibers expressing dMyHC in the dyW-L158
mice appeared to have a proper basement membrane as
indicated by laminin-γ1 staining (red), whereas in non-
treated dyW/dyW mice, dMyHC staining was often punc-
tated and the basement membrane appeared disrupted,
indicating that the fibers fail to complete regeneration
(Figure 4B). In both triceps and diaphragm muscle,
L-158809 clearly increased the number of intact
dMyHC-positive fibers (Figure 4C), suggesting that
regeneration was improved by L-158809.To test the effect of L-158809 on the regenerative cap-
acity, the TA muscle was injured by injection of notexin.
Four days after injury, only a few dMyHC-positive fibers
were found in dyW/dyW mice, whereas many were
present after L-158809 treatment or in WT muscle
(Figure 4D). The number of regenerating fibers increased
from 61 ± 14 in untreated to 490 ± 25 in L-158809-treated
dyW/dyW TA muscle (Figure 4E). Thus, L-158809-mediated
TGF-β inhibition improved the regeneration capacity in
muscles of dyW/dyW mice. Because a similar improve-
ment in muscle regeneration in dyW/dyW mice has also
been reported for treatments that inhibited apoptosis
[47], we also tested whether L-158809 would influence
the number of apoptotic nuclei. However, we could not
detect any effect of this treatment on the number of
terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling-positive myonuclei (see Additional file 1:
Figure S1), indicating that L-158809 does not affect this
pathway.
Effect of L-158809 on overall health of dyW/dyW mice
Finally, we tested whether there was any improvement
in motor function and overall health in L-158809-
treated dyW/dyW mice, and found that L-158809
increased the body weight of dyW/dyW mice, by 2 g
(Figure 4F). However, age-matched WT animals still
weighed more than twice as much. The muscle strength
of dyW/dyW mice, measured as the time the animals
could stay on a vertical grid, was doubled by treatment
with L-158809 from 26 seconds to 51 seconds
(Figure 4G); however, the WT animals far exceeded the
time measured with L-158809-treated dyW/dyW mice,
normally staying more than 180 seconds on the grid. In
the 10-minute open-field locomotion test L-158809-
treated mice were more active and explored the new sur-
roundings for 5 minutes, whereas untreated MDC1A
mice were active only for 3.5 minutes (Figure 4H). Thus,
the ameliorating effect of L-158809 on muscle histology
is sufficient to improve body and muscle condition of
dyW/dyW mice.
Discussion
Muscular dystrophies are caused by mutations in many
different genes but they are often accompanied by a
strong inflammatory and fibrotic response, which might
Figure 3 L-158809 reduced muscle-fiber loss but did not change fiber-size distribution in dyW/dyW muscles. (A) L-158809 (dyW-L158)
stabilized the loss of muscle fibers in dyW/dyW triceps muscle, but only tended to reduce fiber loss in the diaphragm (n = 6). (B,C) L-158809 did
not normalize the shift of fiber sizes to smaller fibers, either (B) in triceps or (C) in diaphragm muscle of dyW/dyW mice (n ≥ 4). (D) The minimal
Feret`s diameter coefficient was unchanged by L-158809 (n ≥ 4). (E) L-158809 increased the cross-sectional area in both mid-belly triceps
(P = 0.0007) and diaphragm (P = 0.0024) muscles (n ≥ 4). All values represent the mean ± SEM. P-values (one-way ANOVA): **P ≤ 0.001;
* P ≤ 0.05; n.s. (non-significant) P > 0.05.
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TGF-β signaling has been shown to be upregulated in
several muscle diseases [8-10], and is known to inhibit
myoblast differentiation and promote fibrosis, and also
to impair regeneration by inhibiting satellite cell activa-
tion, proliferation, and differentiation [3,4].
In this study, we found that TGF-β signaling, including
increased levels of TGF-β and of the phosphorylated
forms of Smad2 and Smad3, was also enhanced in the
severe dyW/dyW mouse model of MDC1A (Figure 1).
These data are in good agreement with previous reports
that TGF-β levels are also upregulated in the muscles
of human patients with MDC1A [38] and in the mild
dy2J/dy2J mouse model [37]. As in the study on dy2J/dy2J
mice, we found an increase in the TGF-β-activating pro-
tease TSP-1, indicating that the elevation of TGF-β is
probably caused by the activation of AT1, as production
of TSP-1 precedes TGF-β activation in this pathway
[1,2,44,45]. Indeed, inhibition of AT1 signaling by oral
administration of L-158809 for only 3 weeks was suffi-
cient to lower the amount of TSP-1 in muscle basement
membrane and to normalize TGF-β levels and Smad2/3
phosphorylation (Figure 1). These experiments provide
strong evidence that the AT1-TSP-TGF-β axis is also
activated in MDC1A and they are in accordance withthe decreased TGF-β levels and Smad2/3 phosphoryl-
ation seen in dy2J/dy2J mice [37]. Previous work in kid-
ney [44] has shown that the AT1-mediated increase in
TSP-1 involves the MAPK pathway. This pathway may
also be active in MDC1A, as the MAPKs ERK1/2, p38
and JNK are all increased in dy2J/dy2J mice, and this in-
crease can be inhibited by losartan [37].
Angiotensin II type 1 receptor antagonists have a strong
effect on muscle regeneration in dyW/dyW mice
Increased TGF-β signaling inhibits activation of satellite
cells [48] and promotes differentiation of myogenic into
fibrotic cells in injured skeletal muscles [3], indicating that
TGF-β-dependent fibrosis is associated with impaired
muscle regeneration. In mouse models of MFS and
Duchenne muscular dystrophy (DMD), losartan treatment
restored the muscle-regeneration capacity after cardiotoxin-
induced muscle injury [1]. In mice with sarcopenia, losartan
restored the necessary downregulation of Pax7 and MyoD
and upregulation of p21 and myogenin, which are required
for successful completion of regeneration of injured muscle,
by modulating TGF-β signaling both via Smad2/Smad3
phosphorylation and via activation of MAPKs [6,13].
Muscle regeneration is largely impaired in MDC1A, and we
have recently shown that the main effect of anti-apoptosis
Figure 4 (See legend on next page.)
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Figure 4 L-158809 improved muscle regeneration, body weight, locomotion, and muscle strength in dyW/dyW mice. (A) L-158809
(dyW-L158) did not significantly affect the number of centrally nucleated fibers (CNF) in either triceps or diaphragm muscle of dyW/dyW mice
(n ≥ 4). (B) Staining of diaphragm muscle for the regeneration marker developmental myosin heavy chain (dMyHC; green), the basement
membrane marker laminin-γ1 (red), and the nuclear marker 4',6'-diamidino-2-phenylindole hydrochloride (DAPI) (blue). L-158809 enabled
damaged dyW/dyW muscle fibers to regenerate, whereas in non-treated dyW/dyW muscle many dMyHC-expressing cells continued degenerating.
(C) L-158809 application strongly increased the number of intact regenerating muscle fibers in dyW/dyW mice (n ≥ 4). (D) Tibialis anterior (TA)
muscle stained for dMyHC (green), laminin-γ1 (red), and DAPI four days after notexin-induced injury. L-158809 increased the regenerative capacity
of damaged dyW/dyW muscle. (E) The number of dMyHC-expressing fibers in TA muscle of dyW/dyW mice 5 days after notexin injection was more
than 8 times higher in L-158809 treated dyW/dyW mice but was still lower than in controls (n = 3). (F) L-158809 increased the average body
weight of dyW/dyW mice from 7.6 g to 9.5 g, although age-matched wild-type (WT) mice weigh more than 20 g. (n ≥ 12). (G). L-158809 doubled
the time a dyW/dyW mouse could hold itself on a vertical grid, from 26 seconds to 51 seconds (P = 0.0001) (n ≥ 14). (H) L-158809 increased the
time dyW/dyW mice explored an unknown surrounding (P = 0.0004) within 10 minutes (n ≥ 12). All values represent the mean ± SEM (n ≥ 4).
One-way ANOVA: **P ≤ 0.001; * P ≤ 0.05; n.s. (non-significant) P > 0.05. Scale bar = 50 μm, if not indicated differently.
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during the regeneration process [47]. In addition, this
previous work also provided evidence that the cell death
prevention by anti-apoptosis treatment had a synergistic
effect when combined with the re-establishment of the con-
nection between the basement membrane and the muscle
membrane by mini-agrin [47].
In the current study, we found evidence that AT1 block-
ade by L-158809 also ameliorated the muscle regeneration
capacity in dyW/dyW mice. Importantly, we found that
L-158809 treatment enabled newly formed muscle fibers
to stay intact and to complete regeneration, whereas
non-treated dyW/dyW fibers started to regenerate, but
then turned into fibrotic cells. The beneficial effect of
L-158809 on regeneration is superior to that seen in
dyW/dyW mice treated with an apoptosis inhibitor alone
[47], and reached almost the same efficacy as the
combination of apoptosis inhibition and mini-agrin [47].
Our observation of a relatively strong beneficial effect of
AT1 antagonists on muscle regeneration is in good
accordance with the finding in mice with sarcopenia, in
which losartan enabled the regeneration of skeletal muscle
by fostering satellite cells to transit from a proliferation
stage into the differentiation process [13]. Our finding that
L-158809 treatment lowered the number of centrally
located myonuclei suggests that AT1 blockade might also
prevent necrosis of muscle fibers.
Effect of Angiotensin II receptor type 1 antagonist on
fibrosis, inflammation, and overall muscle function
Previous work has provided evidence that AT1 antagonists
can ameliorate disease in mouse models of MFS and
DMD and in mice with sarcopenia [1,13-15]. We found
that 4 weeks of L-158809 treatment decreased fibrosis
from 19.7% to 8.1% in triceps and from 23.3% to 10% in
diaphragm muscle, and thereby prevented the characteristic
inflammatory response. Similarly, 12 weeks of losartan
treatment reduced the fibrotic area in dy2J/dy2J by
approximately 4% [37]. In addition, L-158809 treatment in
dyW/dyW mice corrected some of the histologicalhallmarks of the condition, such as fiber loss and muscle
area. In contrast to its effects in mdx mice, L-158809 did
not correct the shift of the fiber-size distribution to smal-
ler fibers in dyW/dyW mice. This phenomenon was due to
the presence of many newly formed regenerating
(dMyHC-positive) fibers that were not grown to full size.
Treatment with L-158809 also resulted in a significant
functional improvement in skeletal muscle, manifesting as
increased locomotor activity and increased grip strength.
Interestingly, an improvement of the hind-limb and fore-
limb strength was also seen in the dy2J/dy2J mouse model
of MDC1A [37].
Therapeutic potential of the different treatment options
The highest potential to restore function in mouse models
for MDC1A is the body-wide, transgenic expression of
laminin-α1, which largely cures the disease [26,27]. How-
ever, because the cDNA encoding laminin-α1 is more than
9 kb in size, its use in gene therapy is challenging, and no
successful attempts in creating smaller versions of the
functional protein have been reported. Another very
effective treatment option is the muscle-specific overex-
pression of a miniaturized form of agrin (mini-agrin),
specifically designed to structurally reconnect the cell
surface protein α-dystroglycan to laminins in the basement
membrane [19,21,25]. Finally, overexpression of insulin-
like growth factor (IGF)-1 also ameliorates disease and
prolongs life span [49], but its efficacy is clearly lower than
that of mini-agrin. This lower efficacy is probably based on
the fact that IGF-1 interferes with rather late events in the
course of the disease, whereas mini-agrin tackles the struc-
tural deficits that are the primary cause of the muscular
dystrophy. Recombinant AAV-based gene therapy with
mini-agrin was shown to be successful in dyW/dyW mice
[28]. However, the use of gene therapy in clinics has been
rather slow, and thus delivery of mini-agrin to the muscles
of patients with MDC1A remains difficult.
This difficulty in translating gene therapy into clinics
has led to attempts to interfere with disease progression
using protein therapy and pharmacological compounds.
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efficacious in dyW/dyW mice is the systemic delivery of
laminin-111 (heterotrimer of the α1, β1, and γ1 chains).
In those studies, laminin-111 reached the skeletal
muscles, improved muscle histology, and prolonged life
span [50]. Pharmacological approaches include the use of
the apoptosis inhibitors omigapil [30] or of doxycycline or
minocycline [31] to treat dyW/dyW mice. In both studies,
there was a clear effect on functional parameters and on
the longevity of the mice; however, the efficacy of either
treatment was much lower than in dyW/dyW mice expres-
sing mini-agrin [47].
Another consequence of muscular dystrophies is a
severe muscle-wasting. Preservation of muscle mass
depends on the proper balance between protein synthe-
sis and protein degradation [51]. Thus, muscle wasting
can be due to a prevalence of protein degradation, and
based on this idea, pharmacological inhibition of the two
main systems involved in protein degradation, the pro-
teasomal and the autophagic pathway, has been tested in
the preclinical mouse models for MDC1A. Again, inter-
ference with either of those pathways ameliorated dis-
ease progression [33,34]. It is, however, questionable if
such an approach is a good option for the treatment of
patients with MDC1A, as inhibition of proteosomal and
autophagosomal degradation has a strong likelihood of
causing severe side-effects.
In the current study, we provide evidence that AT1
antagonists also provide benefit to dyW/dyW mice. Our
results are similar to those of other researchers who
tested inhibition of TGF-β-induced fibrosis by intraperi-
toneal injection of halofuginone in the milder dy2J/dy2J
mouse model of MDC1A [36]. Halofuginone blocked
TGF-β-mediated collagen synthesis, prevented muscle
fibrosis, and improved the performance of both muscles
and animals. In addition, the same group also used losar-
tan to block TGF-β-signaling and this also showed bene-
fit in dy2J/dy2J mice [37]. Thus, our work is an important
confirmation of efficacy of AT1 antagonists in the more
severe mouse model of MDC1A.
It is difficult to compare studies that were performed
in dyW/dyW mice with those using the more severe dy3K/
dy3K mouse model or the much milder dy2J/dy2J model.
As our current study used dyW/dyW mice, it can be com-
pared with those using the pharmacological apoptosis
inhibitors omigapil or doxycycline. A detailed analysis of
those studies indicates that all of the treatments are of
comparable benefit to the mice. For example, they all
increased body weight by approximately 2 g and in the
open-field locomotion test, both L-158809 and omigapil
increased activity time by 1.5 minutes. Treatment with
omigapil and doxycycline approximately doubled the
lifespan of dyW/dyW mice. Because of changes in the
laws regarding animal testing, we could not study thesurvival in a large cohort of animals and could only rec-
ord age at death in four cases of L-158809-treated dyW/
dyW mice. Nevertheless, all four mice lived at least
5 weeks longer than the untreated dyW/dyW mice
(~10 weeks in average). Thus, as L-158809 or losartan
does not act on apoptosis (see Additional file 1: Figure
S1), it remains to be tested whether a combination of
losartan and omigapil could provide an additive benefit
in dyW/dyW mice. The fact that losartan is well tolerated
in all age groups and that omigapil has proven to be safe
in clinical trials of patients with Parkinson’s disease and
those with amyotrophic lateral sclerosis [52,53], makes
such a combination attractive for further clinical trials.
Conclusion
In this study, we investigated the efficacy of AT1 antago-
nists in the most widely used mouse model of MDC1A.
The benefits of the therapy included decreased fibrosis
and inflammation, improved muscle regeneration (which
leads to preservation of muscle-fiber number), and
improved locomotion and grip strength. The AT1 antag-
onist losartan is an approved anti-hypertensive drug that
is well tolerated, including in children. And, importantly,
losartan harbors fewer potential side-effects than any
other pharmacological options that have been tested to
date in preclinical mouse models of MDC1A. Therefore,
AT1 blockade could provide a supportive treatment that
alleviates some of the pathology in patients with
MDC1A in the near future.
Additional file
Additional file 1: Figure S1.
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